Format

Send to

Choose Destination
Clin Chest Med. 2015 Dec;36(4):703-14. doi: 10.1016/j.ccm.2015.08.011. Epub 2015 Oct 9.

Pulmonary Hypertension in Sarcoidosis.

Author information

1
Department of Medicine, University of Cincinnati, 1001 Holmes Eden Avenue, Cincinnati, OH 45220, USA. Electronic address: bob.baughman@uc.edu.
2
Ohio Heart and Cardiovascular Center, Christ Hospital, Auburn Avenue, Cincinnati, OH 45219, USA.
3
Advanced Lung Disease, INOVA Medical Care, 3300 Gallows Road, Falls Church, VA 22042, USA.

Abstract

Pulmonary hypertension is a complication of sarcoidosis leading to dyspnea and associated with increased morbidity and mortality. Sarcoidosis-associated pulmonary hypertension (SAPH) can be due to several factors, including vascular involvement by the granulomatous inflammation, compression of the pulmonary arteries by adenopathy, fibrotic changes within the lung, and left ventricular diastolic dysfunction. Several case series have suggested that some patients with SAPH benefit from specific therapy for pulmonary hypertension. A randomized, placebo-controlled trial found 16 weeks' bosentan therapy to be associated with significant improvement in pulmonary artery pressure. Future studies may better define who would respond to treatment of pulmonary hypertension.

KEYWORDS:

Bosentan; Dyspnea; Pulmonary hypertension; Sarcoidosis

PMID:
26593143
DOI:
10.1016/j.ccm.2015.08.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center